The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials

Frederick Lansigan, Ian Barak, Brandelyn Pitcher, Sin Ho Jung, Bruce D. Cheson, Myron Czuczman, Peter Martin, Eric Hsi, Heiko Schöder, Scott Smith, Nancy L. Bartlett, John P. Leonard, Kristie A. Blum

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Follicular lymphoma (FL) patients treated with firstline R-CHOP who experience progression of disease (POD) within 2 years have a shorter survival than those who do not have POD within 2 years. Whether this observation holds for patients treated initially with biologic immunotherapy alone is unknown. We performed a retrospective analysis of 174 patients pooled from three frontline rituximab (R)-based nonchemotherapy doublet trials: R-galiximab (Anti-CD80, CALGB 50402), R-epratuzumab (Anti-CD22, CALGB 50701), and R-lenalidomide (CALGB 50803) to determine outcomes of early progressors and risk factors for early POD, defined as progression within 24 months from study entry. Twenty-eight percent (48/174) of patients had early POD. After adjusting for the Follicular Lymphoma International Prognostic Index (FLIPI), patients with early POD from study entry had a worse OS compared with patients who did not progress within 2 years (HR = 4.33 (95% CI 1.50-12.5), P = 0.007). For early POD, the 2-year survival was 80% vs 99% for nonearly POD, and the 5-year survival was 74% vs 90%, respectively. These findings suggest that the adverse survival of patients with early POD may be independent of initial treatment modality.

Original languageEnglish
Pages (from-to)165-173
Number of pages9
JournalCancer medicine
Volume8
Issue number1
DOIs
StatePublished - Jan 2019

Keywords

  • PFS24
  • biologic agents
  • early progression
  • follicular lymphoma
  • immunotherapy

Fingerprint

Dive into the research topics of 'The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials'. Together they form a unique fingerprint.

Cite this